Recurrence of Bladder Cancer After Transurethral Resection With Hexvix
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00785694|
Recruitment Status : Withdrawn (Rejected ethics approval in UK and Holland)
First Posted : November 5, 2008
Last Update Posted : April 24, 2015
|Condition or disease||Intervention/treatment||Phase|
|Bladder Cancer||Drug: hexaminolevulinate||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Recurrence of Bladder Cancer After Transurethral Resection With Hexvix|
|Study Start Date :||December 2008|
|Actual Primary Completion Date :||August 2011|
|Actual Study Completion Date :||August 2011|
One instillation of mitomycin C after transurethral resection in white and blue fluorescence light with Hexvix.
Instillation of 50mL of 8mM Hexvix into the bladder through a catheter.
Other Name: Hexvix
No Intervention: A
Multiple instillations of mitomycin C after transurethral resection in white light alone.
- Rate of bladder cancer recurrence [ Time Frame: 12 Months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00785694
|GE Healthcare Medical Diagnostics|
|Velizy Cedex, Morane Saulnier, France, 78457|
|Study Director:||Jean-Paul Antonini||GE Healthcare|